{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:05:58Z","timestamp":1789362358581,"version":"build-2803163510"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the relationship between gynaecomastia and testosterone levels in patients with biochemically recurrent prostate cancer treated with androgen receptor pathway inhibitor (ARPI) monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This analysis evaluates changes in serum testosterone and the incidence of gynaecomastia. Patients with biochemically recurrent prostate cancer were given 3\u2009months of enzalutamide intermittently with no androgen deprivation. Serum testosterone was within the normal range. Testosterone and adverse events were monitored prospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 38 patients were enrolled with a median age of 64.6\u2009years, median (range) serum prostate\u2010specific antigen level of 4.38\u2009(2.01\u201319.43)\u2009ng\/mL, and median (range) serum testosterone level of 316\u2009(167\u2013723)\u2009ng\/dL. Testosterone had a median peak of 832.5\u2009ng\/dL (median increase of 63%). Gynaecomastia symptoms were reported in 16 (42%) patients. There was no correlation with either peak testosterone level or duration of elevated testosterone and gynaecomastia. Patients with gynaecomastia with Course 1 of therapy did not fully predict the incidence of gynaecomastia for Course 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, there is no direct correlation between ARPI monotherapy\u2010associated testosterone elevation and the incidence of gynaecomastia. The interactions of ARPI monotherapy, gynaecomastia, and testosterone elevation are more nuanced than previously thought and require further study to optimise ARPI monotherapy in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70443","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:46:28Z","timestamp":1789361188000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity"],"prefix":"10.1111","author":[{"given":"Jennifer L.","family":"Marte","sequence":"first","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3252-7854","authenticated-orcid":false,"given":"Amy","family":"Hankin","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Williams","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-1332","authenticated-orcid":false,"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-689X","authenticated-orcid":false,"given":"Marijo","family":"Bilusic","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Cordes","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2428-5613","authenticated-orcid":false,"given":"William D.","family":"Figg","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A.","family":"Madan","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-0206","authenticated-orcid":false,"given":"Melissa L.","family":"Abel","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health  Bethesda MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller CJ","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate\u2010specific antigen recurrence after radical prostatectomy: long\u2010term follow\u2010up","volume":"109","author":"Antonarakis ES","year":"2012","journal-title":"BJU Int"},{"key":"e_1_2_9_4_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2016.34.15_suppl.e16587","article-title":"PSA doubling time (PSADT) \u22646 months to identify a subgroup of men with biochemically\u2010recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET)","volume":"34","author":"Suzman DL","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_5_1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook JM","year":"2012","journal-title":"N Engl J Med"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland SJ","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1200\/JCO.2025.43.5_suppl.150","article-title":"Darolutamide monotherapy in patients with castration\u2010sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): ARAMON lead\u2010in phase results","volume":"43","author":"Laccetti AL","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_8_1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","article-title":"A phase 2 randomized open\u2010label study of Oral Darolutamide monotherapy versus androgen deprivation therapy in men with hormone\u2010sensitive prostate cancer (EORTC\u2010GUCG 1532)","volume":"7","author":"Tombal BF","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.24.01134","article-title":"Systemic treatment for biochemical recurrence of localized prostate cancer: do not EMBARK on when, if the answer is how","volume":"42","author":"Tombal B","year":"2024","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","first-page":"e001556","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short\u2010course enzalutamide alone and with immunotherapy in non\u2010metastatic castration sensitive prostate cancer","volume":"9","author":"Madan RA","year":"2021","journal-title":"J Immunother Cancer"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euo.2024.06.001","article-title":"Enzalutamide monotherapy in the EMBARK trial should Be practice\u2010changing and existing data suggest how to mitigate toxicity","volume":"7","author":"Cordes LM","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"e_1_2_9_12_1","article-title":"Randomized, open\u2010label phase 2 study of Apalutamide plus androgen deprivation therapy versus Apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer","volume":"2022","author":"Aggarwal R","year":"2022","journal-title":"Prostate Cancer (Auckl)"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac\u2010VF: a vector\u2010based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan RA","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","volume":"394","author":"Shore ND","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bju.16632","article-title":"Selective treatment de\u2010escalation in advanced prostate cancer: have we come full circle?","volume":"135","author":"Chong B","year":"2025","journal-title":"BJU Int"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"EVIDoa2500109","DOI":"10.1056\/EVIDoa2500109","article-title":"Age and treatment intensification in metastatic hormone\u2010sensitive prostate cancer","volume":"4","author":"Morgans AK","year":"2025","journal-title":"NEJM Evid"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70443","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70443","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:46:39Z","timestamp":1789361199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":15,"alternative-id":["10.1111\/bju.70443"],"URL":"https:\/\/doi.org\/10.1111\/bju.70443","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"assertion":[{"value":"2026-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70443"}}